Elan Corp (ELN) Higher After Goldman Adds The Stock To Its Conviction Buy List
More News related to ELN
- Elan and Biogen Idec Initiate First Clinical Trial of TYSABRI(R) in Oncology
- Notable Analyst Rating Changes 8/29: CBT, NZ, INCY Upgraded; WBD, ENER, WSM Downgraded
- Pre-Open Movers 8/29: Dell Falls On Earnings/Margin Miss, Magma Design (LAVA) Down on Results/Guidance
- Morgan Stanley Starts Elan (ELN) at Overweight
- FDA Issues Complete Response Letter for Paliperidone Palmitate for the Treatment of Schizophrenia
More News related to WYE
- Susquehanna Initiates Coverage on Targanta Therapeutics (TARG) with a Neutral
- Amgen and Wyeth Statement on the FDA Safety Announcement Regarding Tumor Necrosis Factor (TNF) Blockers
- Wyeth Names Daniel J. McIntyre Vice President, Corporate Communications
- ARGUS Maintains Hold Rating on Wyeth (WYE)
- Brodsky & Smith, LLC Announces Investigation of Wyeth Corp. for Violation of Federal Securities Laws
Shares of Elan Corp. plc (NYSE: ELN) are 3% mid-day today after Goldman Sachs added the stock to their Conviction Buy List, citing prospects of the company's Alzheimer's drug bapineuzumab.
Recently, Elan and partner Wyeth (NYSE: WYE) announced encouraging preliminary findings from a Phase 2 study of bapineuzumab in patients with mild to moderate Alzheimer's disease. In the 18-month trial, bapineuzumab appeared to have clinical activity in treating Alzheimer's disease.
The Goldman analyst suggested bapineuzumab could also be effective in pre-Alzheimer's disease conditions.
Related Categories
Analyst CommentsInsiders' Blog
Stocks Mentioned
+0.18
-0.24Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
